Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 1
1989 1
1990 1
1991 3
1992 4
1993 3
1994 3
1995 1
1996 1
1997 1
1998 4
1999 1
2000 1
2001 1
2002 2
2003 5
2005 7
2006 11
2007 3
2008 4
2009 5
2010 10
2011 16
2012 6
2013 8
2014 17
2015 24
2016 15
2017 16
2018 20
2019 26
2020 29
2021 32
2022 19
2023 18
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

289 results

Results by year

Filters applied: . Clear all
Page 1
Methodical Manipulation of the TME in Ovarian Cancer.
Soberanis Pina P, Oza AM. Soberanis Pina P, et al. Among authors: oza am. Clin Cancer Res. 2024 Jan 5;30(1):12-16. doi: 10.1158/1078-0432.CCR-23-2365. Clin Cancer Res. 2024. PMID: 37939000
Heterogeneity and treatment landscape of ovarian carcinoma.
Veneziani AC, Gonzalez-Ochoa E, Alqaisi H, Madariaga A, Bhat G, Rouzbahman M, Sneha S, Oza AM. Veneziani AC, et al. Among authors: oza am. Nat Rev Clin Oncol. 2023 Dec;20(12):820-842. doi: 10.1038/s41571-023-00819-1. Epub 2023 Oct 2. Nat Rev Clin Oncol. 2023. PMID: 37783747 Review.
Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib versus Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer.
Grisham RN, Vergote I, Banerjee S, Drill E, Kalbacher E, Mirza MR, Romero I, Vuylsteke P, Coleman RL, Hilpert F, Oza AM, Westermann A, Oehler MK, Pignata S, Aghajanian C, Colombo N, Cibula D, Moore KN, Del Campo JM, Berger R, Marth C, Sehouli J, O'Malley DM, Churruca C, Kristensen G, Clamp A, Farley J, Iyer G, Ray-Coquard I, Monk BJ. Grisham RN, et al. Among authors: oza am. Clin Cancer Res. 2023 Oct 13;29(20):4068-4075. doi: 10.1158/1078-0432.CCR-23-0621. Clin Cancer Res. 2023. PMID: 37581616 Free PMC article.
Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer.
Gonzalez-Ochoa E, Veneziani AC, Oza AM. Gonzalez-Ochoa E, et al. Among authors: oza am. Clin Med Insights Oncol. 2023 Jul 25;17:11795549231187264. doi: 10.1177/11795549231187264. eCollection 2023. Clin Med Insights Oncol. 2023. PMID: 37528890 Free PMC article. Review.
First-in-human Study of AZD5153, A Small-molecule Inhibitor of Bromodomain Protein 4, in Patients with Relapsed/Refractory Malignant Solid Tumors and Lymphoma.
Hamilton EP, Wang JS, Oza AM, Patel MR, Ulahannan SV, Bauer T, Karlix JL, Zeron-Medina J, Fabbri G, Marco-Casanova P, Moorthy G, Hattersley MM, Littlewood GM, Mitchell P, Saeh J, Pouliot GP, Moore KN. Hamilton EP, et al. Among authors: oza am. Mol Cancer Ther. 2023 Oct 2;22(10):1154-1165. doi: 10.1158/1535-7163.MCT-23-0065. Mol Cancer Ther. 2023. PMID: 37486983 Free PMC article. Clinical Trial.
A phase I study of the Wee1 kinase inhibitor adavosertib (AZD1775) in combination with chemoradiation in cervical, upper vaginal, and uterine cancers.
Gonzalez-Ochoa E, Milosevic M, Corr B, Abbruzzese JL, Girda E, Miller RW, Croke J, Mackay H, Lee YC, Bowering V, Ramsahai J, Wang L, D'Souza A, Kunos CA, Oza AM, Lheureux S. Gonzalez-Ochoa E, et al. Among authors: oza am. Int J Gynecol Cancer. 2023 Aug 7;33(8):1208-1214. doi: 10.1136/ijgc-2023-004491. Int J Gynecol Cancer. 2023. PMID: 37380217 Free PMC article. Clinical Trial.
289 results